1. |
CYC Pak et al: Update of Fluoride in the Treatment of Osteoporosis.
The Endocrinologist 8:15-20, 1998. |
2. |
M Kleerekoper: The Role of Fluoride in the Prevention of Osteoporosis.
Endocrinol Metab Clin North Am 27:441-52, 1998. |
3. |
FDA Endocrinologic and Metabolic Drugs Advisory Committee Meeting #61,
Silver Springs, MD, November 17, 1995. Transcript, 207pp:NDA 19-975 Slow
Fluoride (Committee unanimously recommended approval; p.24-bioavailable
dosage 9mgF/day) |
3a. |
MG Grodberg: Historical Comment. Ibid, pp. 12-16. |
4. |
M Kleerekoper: Editorial - Osteoporosis and The Primary Care Physician:
Time to Bone Up, Ann Int med 123:466-467, 1995. |
5. |
National Osteoporosis Foundation: Treatment Update: Osteoporosis Drugs
Approved by FDA. Osteoporosis Clinical Updates 1:4, 1995. |
6. |
CYC Pak et al: Anabolic Effects of Fluoride on Bone. Trends in Endocrinol
Metabolism 6:229-234, 1995./Slow-Release Sodium Fluoride in Osteoporosis,
J Bone Mineral Research 11:561-564, 1996./Sustained Release Sodium Fluoride
in the Management of Established Postmenopausal Osteoporosis. The American
Journal of Medical Sciences 313:23-32, 1997. |
7. |
C Nagant de Deuxchaisnes and JP Devogelaer: Restorative Therapy of
Osteopososis (in H. Broll and M.A. Dambacher (eds) - Osteoporosis: A Guide
to Diagnosis and Treatment. Rheumatology. Basel-Karger, 1996, vol 18, pp207-
264): Fluoride, pp. 215-264. |
8. |
DJ Baylink: Slow Release Monofluorophosphate (MFP) As A Bone Formation
Stimulant for the Treatment of Established Osteoporosis. (In Symposium
on Recent Developments in Osteoporosis Treatment, Annual Meeting of ASBMR,
Seattle, WA, September 7, 1996). |
9. |
E Seeman et al: Present and Future of Osteoporosis Therapy.,
Bone 117, Suppl:235-295, 1995 |
10. |
JD Ringe and PJ Meunier: Editorial--What is the Future for Fluoride
in the Treatment of Osteoporosis? Osteoporosis Int. 5:71-74, 1995 |
1. |
JY Reginster et al: The Effect of Sodium Monofluorophosphate plus Calcium
on Vertebral Fracture Rate in Postmenopausal Women with Moderate Osteoporosis:
A Randomized Controlled Trial. Ann Intern Med 129:1-8, 1998. |
2. |
A Battmann et al: Serum Fluoride and Serum Osteocalcin Levels In Response
to a Novel Sustained Release Monofluorophosphate Preparation: Comparison
with Plain Monofluorophosphate. Osteoporosis Int. 7:48-51, 1997. |
3. |
CYC Pak et al: Treatment of Postmenopausal Osteoporosis with Slow-Release
Sodium Fluoride: Final Report of a Randomized Controlled Trial. Ann Int.
Med 123:401-408, 1995. |
4. |
JE Zerwekh et al: The Effect of Intermittent Slow-Release Sodium Fluoride
and Continuous Calcium Citrate Therapy On Calcitropic Hormones, Biochemical
Markers of Bone Metabolism and Blood Chemistry In Postmenopausal Osteoporosis.
Calcif. Tissue Int. 61:272-278, 1997. |
5. |
CM Schnitzler et al: Fewer Bone Histomorphometric Abnormalities With
Intermittent Than Continuous Slow-Release Sodium Fluoride Therapy. Osteoporosis
7:376-389, 1997. |
6. |
JD Adachi et al: FluorIde Therapy In Prevention of Rheumatoid Arthritis
Induced Bone Loss. J. Rheumatol. 24:2308-2313, 1997. |
7. |
WF Lems et al: Is Addition of Sodium Fluoride To Cyclical Etidronate
Beneficial In The Treatment of Corticorsteroid Induced Osteoporosis? Annals
of the Rheumatic Diseases 56:357-363, 1997. |
8. |
J Farrerons et al: Sodium Fluoride Treatment Is a Major Protector Against
Vertebral and Fractures When Compared With Other Common Treatments of Osteoporosis:
A Longitudinal, Observational Study. Calcif Tissue Int 60:250-254, 1997. |